Comparison of the euploidy rate in preimplantation genetic testing for aneuploidy cycles following progestin-primed versus gonadotropin-releasing hormone antagonist protocol: a randomized controlled study [PDF]
Reproductive Biology and EndocrinologyBackground Progestins can block endogenous luteinizing hormone secretion from the pituitary gland and have shown similar efficacy in terms of collecting competent oocytes and embryos; however, some inconsistencies have been proposed by the previous ...
Lu Wang +7 more
doaj +2 more sources
Adjunctive tacrolimus in the treatment of fungal keratitis requiring therapeutic penetrating keratoplasty [PDF]
American Journal of Ophthalmology Case ReportsObjective: To determine the efficacy of adjunctive topical tacrolimus in improving graft survival and reducing post operative complications in patients with Therapeutic Penetrating Keratoplasty (TPK) for the treatment of fungal keratitis.
S. Josephine Christy +5 more
doaj +2 more sources
Haematologica, 2021 Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL).
Jennifer R. Brown +14 more
doaj +1 more source
Survival Benefit of Intraductal Radiofrequency Ablation for Malignant Biliary Obstruction: A Systematic Review with Meta-Analysis [PDF]
Clinical Endoscopy, 2021 Background/Aims Cholangiocarcinoma (CCA) is a rare but aggressive disease with a poor survival. Recent trials have shown improved survival with intraductal radiofrequency ablation (RFA) therapy.
Byung Hyo Cha +2 more
doaj +1 more source
Haematologica, 2022 Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy studied in patients with multiple myeloma exposed to three classes of treatment in the single-arm CARTITUDE-1 study. To assess the effectiveness of cilta-cel compared to
Maria-Victoria Mateos +22 more
doaj +1 more source
Haematologica, 2023 Tyrosine kinase inhibitor therapy revolutionized chronic myeloid leukemia treatment and showed how targeted therapy and molecular monitoring could be used to substantially improve survival outcomes.
Jerald P. Radich +22 more
doaj +1 more source
An Italian Registry on Risk Factors for Venous Thromboembolism in Blood Donors Clinicaltrials. Gov: Nct03282747 [PDF]
The 25th Biennial International Congress on Thrombosis, 2018 A registry-based study to evaluate prevalence of common risk factors for vein thrombosis among healthy subjects.
Elvira Grandone +12 more
openaire +2 more sources
Haematologica, 2023 NUP98 fusions comprise a family of rare recurrent alterations in AML, associated with adverse outcomes. In order to define the underlying biology and clinical implications of this family of fusions, we performed comprehensive transcriptome, epigenome ...
Eline J.M. Bertrums +36 more
doaj +1 more source
Haematologica, 2020 Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients with relapsed or refractory large
Paolo Strati +18 more
doaj +1 more source
Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160) [PDF]
Hypertension Research, 2009 Higher doses of angiotensin II receptor blockers (ARBs) are expected to exert more protective effects against cardiovascular diseases. However, the significance of treatment of hypertension with high-dose ARB remains to be defined. The OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study was designed to determine whether high-dose ARB ...
Hisao, Ogawa +4 more
openaire +2 more sources